---
document_datetime: 2025-09-18 13:29:25
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lyrica-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lyrica-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.6561278
conversion_datetime: 2025-12-30 00:37:27.378147
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lyrica

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | Notification acc.Article61(3)-Accepted | 15/09/2025                          |                                          | PL                              |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000296271                         | Update of the package leaflet with revised contactdetailsoflocalrepresentative and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |                 |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|
| Variation type IA / EMA/VR/0000285678    | B.III.1.bEuropeanPharmacopoeial TSE Certificate ofsuitabilityfor an active substance/startingmaterial/reagent/ intermediate/or excipient-B.II1.1.b.2 New certificateforastartingmaterial/reagent/ intermediate/or excipient from a new or an already approved manufacturer- Accepted B.II1.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.1I1.1.a.2 Updated certificate from an already approved manufacturer-Accepted B.III.1.a EuropeanPharmacopoeial CertificateofSuitabilitytotherelevantPh. Eur.Monograph-B.IlI.1.a.4 Deletion of certificates(incasemultiplecertificatesexist per material) - Accepted | 06/08/2025 | N/A |                 |
| Variation type IA_IN / EMA/VR/0000242692 | A.5Changeinthename and/or addressof a manufacturer/importer of the finished product (including batch release or quality control testing sites)-A.5.aThe activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 18/02/2025 | N/A | Annex II and PL |

<div style=\"page-break-after: always\"></div>

| for which the manufacturer/importer is responsible include batch release - Accepted   |
|---------------------------------------------------------------------------------------|